01. Actively Recruiting Clinical Trials
Clinical Trials Recruiting Mesothelioma Patients
Participating in a clinical trial allows those who have been diagnosed with a serious illness, such as mesothelioma, to contribute to medical research. Each clinical trial has unique criteria and guidelines that prospective participants must meet in order to be considered for inclusion in the study. Because there are both benefits and risks to participating in a clinical trial it is always best to discuss any interest you may have with your doctor.
02. List of Clinical Trials
List of Clinical Trials Recruiting Mesothelioma Patients
Provided below is a list of active mesothelioma clinical trials that are still recruiting and enrolling participants. Click on a link to learn more about each study and the criteria for participation.
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Conditions: Mesothelioma, Gastrointestinal Neoplasms, Carcinoma, Peritoneal Neoplasms, Appendiceal Neoplasms
Last Updated: September 1, 2021
Status: Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Adenocarcinoma of Lung, Teratoma, Carcinoma, Neuroendocrine, Pheochromocytoma, Seminoma, Choriocarcinoma, Cystadenocarcinoma, Serous, Carcinoma, Endometrioid, Cystadenocarcinoma, Paraganglioma, Chordoma, Hemangiosarcoma, Fibromatosis, Aggressive, Adenocarcinoma, Mucinous, Trophoblastic Neoplasms, Nerve Sheath Neoplasms, Gestational Trophoblastic Disease, Neurofibrosarcoma, Thyroid Neoplasms, Fibroma, Cystadenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Vulvar Neoplasms, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Paget Disease, Extramammary, Carcinoma, Acinar Cell, Adenocarcinoma, Papillary, Adenocarcinoma, Bronchiolo-Alveolar, Neoplasms, Unknown Primary, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Adenocarcinoma, Clear Cell
Last Updated: August 31, 2021
Status: Recruiting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Conditions: Carcinoma, Merkel Cell, Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Small Cell Lung Carcinoma, Mesothelioma, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma
Last Updated: August 31, 2021
Status: Recruiting
Locations: Boston, MA. Detroit, MI. Pittsburgh, PA. Houston, TX. Seattle, WA.
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Conditions: Adenocarcinoma, Mesothelioma, Cholangiocarcinoma
Last Updated: August 28, 2021
Status: Recruiting
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: August 27, 2021
Status: Recruiting
Locations: La Jolla, CA. Atlanta, GA. Chicago, IL. Baltimore, MD. Boston, MA. Boston, MA. Ann Arbor, MI. Saint Louis Park, MN. New York, NY. Cleveland, OH. Philadelphia, PA. Pittsburgh, PA. Nashville, TN. Houston, TX.
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
Conditions: Esophageal Neoplasms, Mesothelioma, Neoplasms
Last Updated: August 25, 2021
Status: Recruiting
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Conditions: Carcinoma, Neoplasms, Small Cell Lung Carcinoma, Endometrial Neoplasms, Thyroid Neoplasms, Mesothelioma, Neuroendocrine Tumors, Cholangiocarcinoma, Colorectal Neoplasms, Salivary Gland Neoplasms, Carcinoid Tumor, Anus Neoplasms, Bile Duct Neoplasms, Vulvar Neoplasms, Thyroid Diseases
Last Updated: August 25, 2021
Status: Recruiting
Locations: Los Angeles, CA. Los Angeles, CA. Orlando, FL. Baltimore, MD. Rockville, MD. Boston, MA. Boston, MA. Boston, MA. New Brunswick, NJ. Houston, TX.
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
Conditions: Neoplasm Metastasis
Last Updated: August 24, 2021
Status: Recruiting
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Conditions: Neoplasms
Last Updated: August 24, 2021
Status: Recruiting
Locations: Scottsdale, AZ. Duarte, CA. Indianapolis, IN. New York, NY. Oklahoma City, OK. Nashville, TN. Houston, TX. San Antonio, TX.
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: August 20, 2021
Status: Recruiting
Locations: Tampa, FL. Boston, MA. Rochester, MN. Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Sleepy Hollow, NY. Uniondale, NY. Houston, TX.
Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
Conditions: Mesothelioma
Last Updated: August 19, 2021
Status: Recruiting
A Study of CPI-0209 in Patients With Advanced Tumors
Conditions: Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Prostatic Neoplasms, Lymphoma, T-Cell, Prostatic Neoplasms, Castration-Resistant
Last Updated: August 17, 2021
Status: Recruiting
Locations: Atlanta, GA. Baltimore, MD. Boston, MA. Boston, MA. Grand Rapids, MI. Hackensack, NJ. Bronx, NY. New York, NY. Cincinnati, OH. San Antonio, TX. Charlottesville, VA. Seattle, WA.
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: August 17, 2021
Status: Recruiting
Locations: Birmingham, AL. Phoenix, AZ. Scottsdale, AZ. Duarte, CA. La Jolla, CA. Los Angeles, CA. Los Angeles, CA. Newport Beach, CA. Aurora, CO. Aventura, FL. Coral Gables, FL. Deerfield Beach, FL. Jacksonville, FL. Miami, FL. Miami, FL. Plantation, FL. Chicago, IL. Chicago, IL. Lexington, KY. Baltimore, MD. Baltimore, MD. Boston, MA. Boston, MA. Rochester, MN. Creve Coeur, MO. Saint Louis, MO. Saint Louis, MO. Saint Peters, MO. Durham, NC. Pittsburgh, PA. Dallas, TX. Salt Lake City, UT.
Cardiac MRI Biomarker Testing (GCC 1618)
Conditions: Mesothelioma, Thymus Neoplasms
Last Updated: August 16, 2021
Status: Recruiting
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pseudomyxoma Peritonei
Last Updated: August 16, 2021
Status: Recruiting
Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
Conditions: Carcinoma, Breast Neoplasms, Melanoma, Carcinoma, Squamous Cell, Adenocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck, Endometrial Neoplasms, Adenocarcinoma of Lung, Thyroid Neoplasms, Esophageal Neoplasms, Cystadenocarcinoma, Carcinosarcoma, Urinary Bladder Neoplasms, Adenomyoepithelioma, Adenocarcinoma, Clear Cell, Cystadenocarcinoma, Serous
Last Updated: August 13, 2021
Status: Recruiting
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Conditions: Mesothelioma
Last Updated: August 11, 2021
Status: Recruiting
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Conditions: Neoplasms
Last Updated: August 11, 2021
Status: Recruiting
Locations: Los Angeles, CA. New York, NY. Houston, TX. San Antonio, TX. Fairfax, VA.
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Conditions: Neoplasms, Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma
Last Updated: August 10, 2021
Status: Recruiting
Locations: Gainesville, FL. Miami, FL. Orlando, FL.
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Conditions: Mesothelioma
Last Updated: August 9, 2021
Status: Recruiting
Intravenous Magnesium in Patients Receiving Cisplatin
Conditions: Mesothelioma
Last Updated: August 2, 2021
Status: Recruiting
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Conditions: Mesothelioma, Wilms Tumor
Last Updated: August 2, 2021
Status: Recruiting
Locations: Basking Ridge, NJ. Middletown, NJ. Commack, NY. Harrison, NY. New York, NY. Uniondale, NY.
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Conditions: Uterine Cervical Neoplasms, Mesothelioma, Carcinoma, Non-Small-Cell Lung, Thymoma, Thymus Neoplasms
Last Updated: July 31, 2021
Status: Recruiting
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Conditions: Neoplasms, Mesothelioma, Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms, Prostatic Neoplasms, Neoplasms, Squamous Cell
Last Updated: July 28, 2021
Status: Recruiting
Locations: Scottsdale, AZ. Santa Monica, CA. Norwich, CT. Boston, MA. Boston, MA. Boston, MA. Danvers, MA. Las Vegas, NV. Oklahoma City, OK. Oklahoma City, OK. Nashville, TN. Nashville, TN. Houston, TX. San Antonio, TX.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Conditions: Carcinoma, Merkel Cell, Carcinoma, Neoplasms, Carcinoma, Squamous Cell, Carcinoma, Renal Cell, Small Cell Lung Carcinoma, Mesothelioma, Nasopharyngeal Carcinoma, Carcinoma, Basal Cell, Esophageal Squamous Cell Carcinoma, Endometrial Neoplasms
Last Updated: July 27, 2021
Status: Recruiting
Locations: Hackensack, NJ. Greenville, SC.
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Conditions: Mesothelioma
Last Updated: July 26, 2021
Status: Recruiting
Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Uniondale, NY.
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Conditions: Carcinoma, Non-Small-Cell Lung, Mesothelioma
Last Updated: July 23, 2021
Status: Recruiting
Rapid Autopsy and Procurement of Cancer Tissue
Conditions: Mesothelioma, Urogenital Neoplasms
Last Updated: July 22, 2021
Status: Recruiting
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Conditions: Carcinoma, Neoplasms, Mesothelioma, Colorectal Neoplasms, Pseudomyxoma Peritonei, Peritoneal Neoplasms
Last Updated: July 21, 2021
Status: Recruiting
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Conditions: Mesothelioma
Last Updated: July 21, 2021
Status: Recruiting
Locations: Tampa, FL. Baltimore, MD. Detroit, MI. Minneapolis, MN.
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: July 19, 2021
Status: Recruiting
The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Mesothelioma
Last Updated: July 19, 2021
Status: Recruiting
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Conditions: Adenocarcinoma, Sarcoma, Mesothelioma, Sarcoma, Ewing, Chondrosarcoma
Last Updated: July 16, 2021
Status: Recruiting
Locations: Scottsdale, AZ. Duarte, CA. Los Angeles, CA. Santa Monica, CA. Aurora, CO. Atlanta, GA. Chicago, IL. Grand Rapids, MI. Houston, TX. San Antonio, TX.
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma
Conditions: Lung Neoplasms, Mesothelioma
Last Updated: July 8, 2021
Status: Recruiting
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: July 6, 2021
Status: Recruiting
Locations: Baltimore, MD. Baltimore, MD. Houston, TX.
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Conditions: Neoplasms, Neoplasm Metastasis
Last Updated: July 1, 2021
Status: Recruiting
Locations: Grand Rapids, MI. Houston, TX. San Antonio, TX.
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: June 29, 2021
Status: Recruiting
CAR T Cells in Mesothelin Expressing Cancers
Conditions: Mesothelioma, Fallopian Tube Neoplasms, Adenocarcinoma of Lung
Last Updated: June 29, 2021
Status: Recruiting
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
Conditions: Carcinoma, Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Stomach Neoplasms, Uterine Cervical Neoplasms, Mesothelioma, Carcinoma, Transitional Cell, Endometrial Neoplasms, Bile Duct Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Penile Neoplasms
Last Updated: June 29, 2021
Status: Recruiting
Locations: Sacramento, CA. Bethesda, MD. Bethesda, MD. Columbus, OH. Pittsburgh, PA. Madison, WI.
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Cholangiocarcinoma
Last Updated: June 28, 2021
Status: Recruiting
Locations: San Francisco, CA. Bethesda, MD. New York, NY. Philadelphia, PA. Nashville, TN. Houston, TX.
UNITO-001-A Phase II Study Niraparib Plus Dostarlimab in HRR/PDL1 Positive MPM/NSCLC
Conditions: Mesothelioma
Last Updated: June 17, 2021
Status: Recruiting
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: June 15, 2021
Status: Recruiting
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Conditions: Carcinoma, Glioblastoma, Mesothelioma, Cholangiocarcinoma, Squamous Cell Carcinoma of Head and Neck
Last Updated: June 10, 2021
Status: Recruiting
Locations: Grand Rapids, MI. San Antonio, TX.
APG-2449 in Patients With Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: June 9, 2021
Status: Recruiting
A Study of SGN-CD228A in Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: May 27, 2021
Status: Recruiting
Locations: Birmingham, AL. Los Angeles, CA. Chicago, IL. Winston-Salem, NC. Cleveland, OH. Portland, OR. Pittsburgh, PA. Sioux Falls, SD. Houston, TX. San Antonio, TX.
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: May 27, 2021
Status: Recruiting
Locations: Tampa, FL. Tampa, FL. Tampa, FL. Chicago, IL. Boston, MA. Rochester, MN. Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. New York, NY. Uniondale, NY. Cleveland, OH. Columbus, OH. Houston, TX. Seattle, WA.
A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
Conditions: Lymphoma, Neoplasms, Sarcoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Mesothelioma, Hematologic Neoplasms, Sarcoma, Synovial, Rhabdoid Tumor, Carcinoma, Medullary
Last Updated: May 26, 2021
Status: Recruiting
Locations: Encinitas, CA. Los Angeles, CA. Chicago, IL. Grand Rapids, MI. Canton, OH. Cincinnati, OH. Dallas, TX.
Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: May 26, 2021
Status: Recruiting
Locations: Buffalo, NY. Philadelphia, PA.
Olaparib in Patients With HRD Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: May 12, 2021
Status: Recruiting
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
Conditions: Stomach Neoplasms, Esophageal Neoplasms, Mesothelioma, Gastrointestinal Stromal Tumors, Anus Neoplasms, Pancreatic Neoplasms, Liver Neoplasms, Carcinoma, Hepatocellular, Gastrointestinal Neoplasms
Last Updated: May 12, 2021
Status: Recruiting
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: April 30, 2021
Status: Recruiting
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
Conditions: Mesothelioma
Last Updated: April 29, 2021
Status: Recruiting
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Conditions: Carcinoma, Melanoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Mesothelioma, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Breast Neoplasms, Lung Neoplasms, Carcinoma, Basal Cell, Squamous Cell Carcinoma of Head and Neck, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Thymoma, Small Cell Lung Carcinoma, Anus Neoplasms, Vulvar Neoplasms
Last Updated: April 28, 2021
Status: Recruiting
Locations: Los Angeles, CA. Los Angeles, CA. San Diego, CA. San Francisco, CA. Atlanta, GA. Chicago, IL. Fairway, KS. Detroit, MI. New York, NY. New York, NY. Portland, OR. Philadelphia, PA. Pittsburgh, PA. Houston, TX. Salt Lake City, UT. Charlottesville, VA. Seattle, WA.
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
Conditions: Neoplasms, Melanoma, Mesothelioma, Skin Neoplasms, Lung Neoplasms, Bone Neoplasms, Genital Neoplasms, Female, Soft Tissue Neoplasms, Endocrine Gland Neoplasms, Pharyngeal Neoplasms, Mouth Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Genital Neoplasms, Male, Sarcoma, Thyroid Diseases, Recurrence
Last Updated: April 28, 2021
Status: Recruiting
Prospective Evaluation of Photon Counting Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Conditions: Mesothelioma, Syndrome, Disease Susceptibility
Last Updated: April 22, 2021
Status: Recruiting
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations
Conditions: Mesothelioma
Last Updated: April 21, 2021
Status: Recruiting
Locations: Houston, TX. San Antonio, TX.
Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
Conditions: Carcinoma, Merkel Cell, Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Squamous Cell, Ovarian Neoplasms, Carcinoma, Hepatocellular, Stomach Neoplasms, Uterine Cervical Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Mesothelioma, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Anus Neoplasms, Thymus Neoplasms, Microsatellite Instability
Last Updated: April 20, 2021
Status: Recruiting
Locations: New Haven, CT. Houston, TX.
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection
Conditions: Mesothelioma
Last Updated: April 11, 2021
Status: Recruiting
Short Neoadjuvant Hemithoracic IMRT for MPM
Conditions: Mesothelioma
Last Updated: April 11, 2021
Status: Recruiting
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
Conditions: Mesothelioma
Last Updated: April 9, 2021
Status: Recruiting
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: April 9, 2021
Status: Recruiting
A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
Conditions: Mesothelioma
Last Updated: April 6, 2021
Status: Recruiting
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: April 6, 2021
Status: Recruiting
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Conditions: Mesothelioma, Pleural Diseases
Last Updated: March 30, 2021
Status: Recruiting
Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY.
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Conditions: Carcinoma, Merkel Cell, Mesothelioma, Neuroendocrine Tumors, Neoplasms, Squamous Cell, Carcinoma, Squamous Cell, Microsatellite Instability
Last Updated: March 28, 2021
Status: Recruiting
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Conditions: Mesothelioma
Last Updated: March 21, 2021
Status: Recruiting
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Conditions: Carcinoma, Merkel Cell, Lymphoma, Carcinoma, Endometrial Neoplasms, Mesothelioma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell
Last Updated: March 15, 2021
Status: Recruiting
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
Conditions: Lymphoma, Carcinoma, Prostatic Neoplasms, Melanoma, Carcinoma, Squamous Cell, Leukemia, Myeloid, Acute, Ovarian Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Stomach Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Adenoid Cystic, Thymoma, Lung Neoplasms
Last Updated: March 11, 2021
Status: Recruiting
Locations: Duarte, CA. Morristown, NJ. New York, NY. Houston, TX. Milwaukee, WI.
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Conditions: Neoplasm Metastasis, Brain Neoplasms, Astrocytoma, Mesothelioma, Cholangiocarcinoma, Esophageal Neoplasms, Thymoma, Tongue Neoplasms, Urologic Neoplasms
Last Updated: March 8, 2021
Status: Recruiting
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Conditions: Mesothelioma
Last Updated: March 8, 2021
Status: Recruiting
Locations: Phoenix, AZ. Los Angeles, CA. San Francisco, CA. Tampa, FL. Chicago, IL. Baltimore, MD. Detroit, MI. Rochester, MN. New York, NY. Houston, TX. Alessandria, Alabama. Milano, Michigan.
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Conditions: Carcinoma, Melanoma, Mesothelioma, Cholangiocarcinoma, Meningioma
Last Updated: March 7, 2021
Status: Recruiting
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
Conditions: Mesothelioma
Last Updated: March 5, 2021
Status: Recruiting
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
Conditions: Mesothelioma
Last Updated: March 2, 2021
Status: Recruiting
Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: February 25, 2021
Status: Recruiting
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
Conditions: Mesothelioma
Last Updated: February 25, 2021
Status: Recruiting
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Conditions: Mesothelioma, Disease Progression
Last Updated: February 25, 2021
Status: Recruiting
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Conditions: Mesothelioma
Last Updated: February 17, 2021
Status: Recruiting
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Conditions: Neoplasms, Mesothelioma, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Biliary Tract Neoplasms
Last Updated: February 11, 2021
Status: Recruiting
DENdritic Cell Immunotherapy for Mesothelioma
Conditions: Mesothelioma
Last Updated: January 26, 2021
Status: Recruiting
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Last Updated: January 22, 2021
Status: Recruiting
First-in-human Study of S-588210 (S-488210+S-488211)
Conditions: Mesothelioma
Last Updated: January 22, 2021
Status: Recruiting
Autologous Dendritic Cell Vaccination in Mesothelioma
Conditions: Mesothelioma
Last Updated: January 15, 2021
Status: Recruiting
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Conditions: Neoplasms, Sarcoma, Mesothelioma, Lung Neoplasms, Esophageal Neoplasms, Neoplasms, Germ Cell and Embryonal, Thymus Neoplasms
Last Updated: January 9, 2021
Status: Recruiting
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
Conditions: Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Esophageal Neoplasms
Last Updated: December 10, 2020
Status: Recruiting
Phase I Trial HIPEC With Nal-irinotecan
Conditions: Mesothelioma, Adenocarcinoma, Mucinous, Cystadenocarcinoma, Pseudomyxoma Peritonei
Last Updated: November 27, 2020
Status: Recruiting
Locations: Lexington, KY. Stony Brook, NY.
Integrated Cancer Repository for Cancer Research
Conditions: Neoplasms, Multiple Myeloma, Pancreatic Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms, Thyroid Neoplasms, Mesothelioma, Neuroendocrine Tumors, Salivary Gland Neoplasms, Anus Neoplasms, Gallbladder Neoplasms, Bile Duct Neoplasms, Oropharyngeal Neoplasms, Nasopharyngeal Neoplasms, Nasopharyngeal Carcinoma, Urethral Neoplasms, Vaginal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Adenomatous Polyposis Coli, Colorectal Neoplasms, Hereditary Nonpolyposis, Testicular Neoplasms, Intestinal Neoplasms, Hypopharyngeal Neoplasms, Penile Neoplasms, Ureteral Neoplasms, Neoplasms, Plasma Cell, Peritoneal Neoplasms, Paranasal Sinus Neoplasms, Duodenal Neoplasms, Neoplasms, Unknown Primary, Lip Neoplasms, Thymus Neoplasms, Paraproteinemias
Last Updated: November 10, 2020
Status: Recruiting
Locations: Colorado Springs, CO. Denver, CO. Durango, CO. Lakewood, CO. Littleton, CO. Longmont, CO. Louisville, CO. Parker, CO. Pueblo, CO. Westminster, CO. Daytona Beach, FL. DeLand, FL. Orange City, FL. Palm Coast, FL. Aurora, IL. Moline, IL. Yorkville, IL. Fort Wayne, IN. Indianapolis, IN. Indianapolis, IN. Indianapolis, IN. Kokomo, IN. Council Bluffs, IA. Davenport, IA. Spencer, IA. Waterloo, IA. Overland Park, KS. New Orleans, LA. Portland, ME. Randallstown, MD. Westminster, MD. Holyoke, MA. Ann Arbor, MI. Aitkin, MN. Brainerd, MN. Duluth, MN. Duluth, MN. Fergus Falls, MN. Marshall, MN. Joplin, MO. Kansas City, MO. Kansas City, MO. Kansas City, MO. Liberty, MO. Saint Joseph, MO. Kalispell, MT. Missoula, MT. Hastings, NE. Norfolk, NE. North Platte, NE. O'Neill, NE. Omaha, NE. Omaha, NE. Omaha, NE. Scottsbluff, NE. Glens Falls, NY. Utica, NY. Fayetteville, NC. Fargo, ND. Minot, ND. Pittsburgh, PA. Aberdeen, SD. Mitchell, SD. Sioux Falls, SD. Sioux Falls, SD. Yankton, SD. Yankton, SD. Yankton, SD. Rutland, VT. Fredericksburg, VA. Appleton, WI. Brookfield, WI. Franklin, WI. Mequon, WI. Milwaukee, WI. Oshkosh, WI. Racine, WI. Wauwatosa, WI.
eRAPID: Online Symptom Reporting in Lung Cancer
Conditions: Lung Neoplasms, Small Cell Lung Carcinoma, Mesothelioma
Last Updated: November 5, 2020
Status: Recruiting
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
Conditions: Carcinoma, Breast Neoplasms, Carcinoma, Squamous Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms, Mesothelioma, Squamous Cell Carcinoma of Head and Neck
Last Updated: October 22, 2020
Status: Recruiting
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Conditions: Mesothelioma
Last Updated: September 25, 2020
Status: Recruiting
Locations: Basking Ridge, NJ. Middletown, NJ. Montvale, NJ. Commack, NY. Harrison, NY. New York, NY. Rockville Centre, NY. Uniondale, NY.
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms
Last Updated: September 15, 2020
Status: Recruiting
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural
Last Updated: September 10, 2020
Status: Recruiting
Dose Individualization of Pemetrexed - IMPROVE-II
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Last Updated: September 10, 2020
Status: Recruiting
Staging Procedures to Diagnose Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural
Last Updated: September 10, 2020
Status: Recruiting
Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma
Conditions: Mesothelioma, Neoplasms, Fibrous Tissue, Solitary Fibrous Tumors, Pleural Neoplasms, Solitary Fibrous Tumor, Pleural
Last Updated: September 10, 2020
Status: Recruiting
Intrapleural Cryotherapy for Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: September 9, 2020
Status: Recruiting
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: August 21, 2020
Status: Recruiting
Rehabilitation by Effort for Patients With Advanced Bronchial Cancer
Conditions: Mesothelioma, Carcinoma, Bronchogenic
Last Updated: July 29, 2020
Status: Recruiting
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Conditions: Mesothelioma
Last Updated: July 27, 2020
Status: Recruiting
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Conditions: Mesothelioma, Fever
Last Updated: July 14, 2020
Status: Recruiting
Dose Individualization of Pemetrexed - IMPROVE-I
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Last Updated: July 10, 2020
Status: Recruiting
Dose Individualization of Pemetrexed - IMPROVE-III
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Last Updated: July 10, 2020
Status: Recruiting
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: June 29, 2020
Status: Recruiting
HMPL-453 in Advanced Malignant Mesothelioma
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: June 12, 2020
Status: Recruiting
Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
Conditions: Mesothelioma
Last Updated: June 11, 2020
Status: Recruiting
Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
Conditions: Carcinoma, Neoplasms, Sarcoma, Glioblastoma, Mesothelioma, Neuroendocrine Tumors, Endometrial Neoplasms, Stomach Neoplasms
Last Updated: June 5, 2020
Status: Recruiting
Locations: Boston, MA.
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Conditions: Mesothelioma, Neuroendocrine Tumors, Thymoma
Last Updated: May 3, 2020
Status: Recruiting
Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed
Conditions: Mesothelioma
Last Updated: December 13, 2019
Status: Recruiting
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Conditions: Leukemia, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Mesothelioma, Sarcoma, Synovial, Esophageal Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms
Last Updated: December 10, 2019
Status: Recruiting
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Conditions: Mesothelioma, Lung Neoplasms
Last Updated: December 2, 2019
Status: Recruiting
Mesothelioma and Radical Surgery 2
Conditions: Mesothelioma
Last Updated: October 28, 2019
Status: Recruiting
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Conditions: Mesothelioma, Pancreatic Neoplasms, Gallbladder Neoplasms, Pseudomyxoma Peritonei, Appendiceal Neoplasms, Pleural Effusion, Ascites
Last Updated: October 7, 2019
Status: Recruiting
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Conditions: Mesothelioma
Last Updated: October 4, 2019
Status: Recruiting
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
Conditions: Mesothelioma, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Uterine Neoplasms, Fever
Last Updated: April 15, 2019
Status: Recruiting
Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
Conditions: Mesothelioma, Carcinoma, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Fever
Last Updated: October 15, 2018
Status: Recruiting
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
Conditions: Mesothelioma, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms
Last Updated: March 16, 2018
Status: Recruiting
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Conditions: Carcinoma, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Carcinoma, Neuroendocrine
Last Updated: November 18, 2016
Status: Recruiting
